Royalty Pharma pays Ferring $300M for 5% royalty on sales of cancer gene therapy Adstiladrin
Ferring Pharmaceuticals is pulling in $300 million and a potential $200 million milestone from Royalty Pharma in exchange for a 5.1% percentage royalty on net sales of its gene therapy Adstiladrin, just as it gears up to roll out the treatment commercially.
The $200 million milestone payment depends on hitting manufacturing goals in 2025, while the royalty payments are expected to end in the early- to mid-2030s. According to Ferring, the money from Royalty Pharma will be used to scale up manufacturing, commercialization and clinical development for the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.